ClinicalTrials.gg
RecruitingNCT06894901Updated Mar 25, 2025

Impact of IIT-SIT on Dengue Clusters

An interventional study of Biological (Male Wolbachia-infected Aedes aegypti) in Dengue, sponsored by National Environment Agency, Singapore. Recruiting at 1 site in Singapore. Per ClinicalTrials.gov, last updated 2025-03-25.

Sponsored by National Environment Agency, Singapore · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
900
Allocation
Randomized
Sex
All
01

Study summary

This randomized controlled trial aims to evaluate the efficacy of Wolbachia-infected male mosquitoes combined with sterile insect technique (IIT-SIT) to mitigate active dengue transmission in Singapore.

Read the detailed description

Aedes-borne diseases are expected to increase in geographical coverage and intensity due to climate change and rapid urbanization. It has been demonstrated that Wolbachia-mediated incompatible insect technique coupled with sterile insect technique (IIT-SIT) is highly effective in suppressing Aedes populations and subsequently reducing dengue risk. However, the efficacy of the tool in mitigating ongoing transmission is unknown.

The researchers outline a randomized controlled trial to be conducted in high-rise public housing estates in Singapore to assess the efficacy of IIT-SIT to mitigate active dengue transmission. Specifically, the study will determine whether the release of male Wolbachia-infected Aedes aegypti mosquitoes can curtail the growth of dengue clusters, defined operationally by the Singapore National Environment Agency (NEA) as two or more reported dengue cases within a 150-meter radius and with illness onset dates within 14 days of each other. This study will randomize eligible clusters into intervention/control arms in real-time. Clusters assigned to the intervention arm will receive IIT-SIT treatment until cluster extinction (i.e. when no further cases are linked to the cluster). This trial closely mimics how IIT-SIT could be used as an additional tool for outbreak management, by treating areas with active dengue transmission in real-time. Conventional vector control measures will be carried out as per NEA's usual outbreak management practices in both intervention and control clusters. The intervention efficacy will be estimated through two primary endpoints: (1) probability of cluster extinction, as estimated from the time-to-cluster extinction among intervention versus control clusters; and (2) final size of the dengue cluster, as estimated by the difference in the final number of dengue cases in intervention versus control clusters.

This study will provide evidence from a randomized controlled trial for the efficacy of IIT-SIT in curbing ongoing transmission and provide an epidemiological basis for integrating IIT-SIT into the existing arsenal of outbreak management tools. The trial will assess the technology's feasibility for operationalization, and identify difficulties in implementation prior to larger-scale use for outbreak control.

02

Conditions studied

  • Dengue

Browse trials for

03

In context

Dengue

283 studies on the registry are indexed under Dengue; 44 are open to participants now.

This study's planned enrollment of 900 is above the median of 132 across 197 interventional studies indexed under Dengue.

Browse Dengue studies →

Lead sponsor

National Environment Agency, Singapore is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Eligible dengue clusters will be limited to public housing estates and with at least 10 dengue cases comprising that dengue cluster before allocation into intervention or control arms. The selected clusters will be in areas with relatively high sector-level GAI of at least 0.2 at the time of the 10th reported case. Additionally, the first 10 cases must be reported within 30 days of the first case. Additionally, clusters must be in areas which have never experienced Wolbachia-Aedes releases and at least 700 m away from existing Wolbachia-Aedes release areas.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
900 participants (estimated)

Study arms

  • Experimental
    Intervention clusters

    Dengue clusters in residential estates that receive releases of male Wolbachia-infected Aedes aegypti

    Biological: Biological (Male Wolbachia-infected Aedes aegypti)

  • No intervention
    Non-intervention clusters

    Dengue clusters in residential estates that do not receive releases of male Wolbachia-infected Aedes aegypti

Interventions

06

What researchers measure

Primary outcomes

  1. Impact of male Wolbachia-Aedes deployments on the time to cluster extinction

    In this analysis, male Wolbachia-Aedes exposure will be considered as a binary classification based on whether the dengue cluster is allocated to the intervention or control arm. Cox proportional hazards models will be used to assess the intervention effect of male Wolbachia-Aedes by estimating the hazards ratio, which compares the probability of cluster extinction between arms from following up clusters from enrolment to cluster extinction.

    Time frame: Up to 3 years

  2. Impact of male Wolbachia-Aedes deployments on final cluster size, as measured by the difference in final cluster size between arms

    In this analysis, male Wolbachia-Aedes exposure will be considered as a binary classification based on whether the dengue cluster is allocated to the intervention or control arm. Negative binomial models will be used to assess the intervention effect of male Wolbachia-Aedes by estimating the average treatment effect of the intervention on the final number of dengue cases in intervention versus control clusters.

    Time frame: Up to 3 years

Secondary outcomes

  1. Impact of male Wolbachia-Aedes deployments on the prevalence of Ae. aegypti/Ae. albopictus mosquitoes

    The study will test whether male Wolbachia-Aedes deployments will effectively suppress Ae. aegypti mosquito populations as well as whether they have an off-target impact on Ae. albopictus mosquito populations in intervention vs. control clusters.

    Time frame: Up to 3 years

  2. Impact of male Wolbachia-Aedes deployments on dengue risk in clusters, measured by odds ratio of Wolbachia exposure distribution among laboratory-confirmed reported dengue cases compared to test-negative controls

    In this analysis, male Wolbachia-Aedes exposure will be considered as a binary classification based on whether a patient's residence is in an dengue cluster receiving intervention or a control cluster, where residence is defined as the primary place where the patient resided at reporting date.

    Time frame: Up to 3 years

  3. Impact of male Wolbachia-Aedes deployments on the individual level reproduction number

    In this analysis, the researchers will use notified and individually geolocated dengue cases to calculate the spatially adjusted time-varying reproduction number, which estimates the number of forward infections caused by an individual.

    Time frame: Up to 3 years

07

Study locations

1 of 1 sites recruiting
  • National Environment Agency
    Singapore, Singapore
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06894901
Lead sponsor
National Environment Agency, Singapore
Collaborators
Ministry of Health, Singapore
Responsible party
Lee Ching Ng (Group Director (Environmental Health Institute), National Environment Agency, Singapore) — Principal investigator
First posted
Mar 25, 2025
Start date
Mar 20, 2025 (estimated)
Primary completion
Jul 20, 2027 (estimated)
Completion
Jan 20, 2028 (estimated)
Last update
Mar 25, 2025

Study contacts

Lee Ching Ng, PhD
Contact
NG_Lee_Ching@nea.gov.sg
+65 67719108
Lee Ching Ng Group Director (Environmental Health Institute), PhD
principal investigator · Environmental Health Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Biological Products

Start the discussion